Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

This study is currently recruiting participants.

Verified February 2013 by Hellenic Oncology Research Group

Study NCT00691379 Information provided by Hellenic Oncology Research Group

First Received on May 29, 2008. Last Updated on February 6, 2013 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Breast Cancer

Additional conditions recognized in this trial

Breast Neoplasms

More general conditions related to this trial

Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases

Interventions listed in this trial

Carboplatin
Bevacizumab
Paclitaxel

More general drug interventions related to this trial

Sponsors listed in this trial